India  

Guidance for Choosing a 4th COVID Shot or the Omicron Booster

Video Credit: Wibbitz Top Stories - Duration: 01:31s - Published
Guidance for Choosing a 4th COVID Shot or the Omicron Booster

Guidance for Choosing a 4th COVID Shot or the Omicron Booster

Guidance for Choosing , a 4th COVID Shot , or the Omicron Booster.

As other nations begin to offer Omicron-specific booster shots, .

Those in the U.S. may be wondering if they should get a fourth booster shot now... ... or wait for a booster that is tailored to the highly-contagious strain to be available in the U.S. Currently, only those over the age of 50 or those between 12 and 50 who are immunocompromised are eligible for a second booster shot.

Currently, only those over the age of 50 or those between 12 and 50 who are immunocompromised are eligible for a second booster shot.

While the Omicron booster should be available in the U.S. sometime this fall.

Health experts recommend that if you're eligible for the booster you should get one as soon as possible.

For those who have not been vaccinated or recently had COVID in the past six months.

Experts recommend a booster in that scenario as well.

For those who are not eligible for the booster and have not opted to get one, .

Experts say waiting for the Omicron booster this fall is a viable option.

They also caution that while the Omicron booster will be made specifically to combat that variant, it won't be full-proof protection.

Boosters against Omicron are not going to be a magic shield, Dr. Shane Crotty, La Jolla Institute for Immunology, via 'The New York Times'.

For those who have received a second booster shot and are considering getting the Omicron booster as well, experts say the extra shot will not make much difference.

If you get a booster now and you get another booster Sept.

15, don’t expect that second shot to do anything, Dr. Shane Crotty, La Jolla Institute for Immunology, via 'The New York Times'


You Might Like


💡 newsR Knowledge: Other News Mentions

SARS-CoV-2 Omicron variant SARS-CoV-2 Omicron variant Type of the virus first detected in November 2021

Pfizer and BioNTech Claim Omicron Booster Is Stronger Than Original Shot [Video]

Pfizer and BioNTech Claim Omicron Booster Is Stronger Than Original Shot

Pfizer and BioNTech Claim, Omicron Booster Is Stronger , Than Original Shot. The companies made the claim via a press release issued on Nov. 4. Based on two company-led studies, the results have not been confirmed by independent scientists. Pfizer and BioNTech claim the results show their booster vaccine can be up to four times more effective for adults over 55. As we head into the holiday season, we hope these updated data will encourage people to seek out a COVID-19 bivalent booster as soon as they are eligible... , Albert Bourla, Pfizer Chairman and CEO, via Pfizer Press Release. ... in order to maintain high levels of protection against the widely circulating Omicron BA.4 and BA.5 sublineages, Albert Bourla, Pfizer Chairman and CEO, via Pfizer Press Release. These updated data also provide confidence in the adaptability of our mRNA platform... , Albert Bourla, Pfizer Chairman and CEO, via Pfizer Press Release. ... and our ability to rapidly update the vaccine to match the most prevalent strains each season, Albert Bourla, Pfizer Chairman and CEO, via Pfizer Press Release. BioNTech's CEO stated that the companies will continue to tailor their vaccines to new COVID variants and subvariants. In the next step and as part of our science-based approach we will continue to evaluate the cross-neutralization of the adapted vaccine against new variants and sublineages. , Professor Ugur Sahin, BioNTech CEO and Co-founder, via Pfizer Press Release. Our goal is to provide broader immunity against COVID-19 caused by SARS-CoV-2, including Omicron and other circulating strains, Professor Ugur Sahin, BioNTech CEO and Co-founder, via Pfizer Press Release. According to the Pfizer press release, . ... the company has shared its data with both the U.S. Food and Drug Administration and the European Medicines Agency

Credit: Wibbitz Top Stories    Duration: 01:30Published
Pfizer To Increase US COVID Vaccine Price to $110–$130 per Dose [Video]

Pfizer To Increase US COVID Vaccine Price to $110–$130 per Dose

Pfizer To Increase US COVID Vaccine Price , to $110–$130 per Dose. Reuters reports that Pfizer executive Angela Lukin made the announcement on Oct. 20. . The new price range, which is nearly quadruple the current cost, will go into effect when the government's purchase program expires. Currently, the U.S. government pays Pfizer/BioNTech $30 per dose. Lukin expects that those who have either private or government-paid insurance will be able to continue to receive the vaccine at little or no cost. We are confident that the U.S. price point of the COVID-19 vaccine reflects its overall cost effectiveness and ensures the price will not be a barrier for access for patients, Angela Lukin, Pfizer executive, via Reuters. According to the CDC, the updated cost will be in line with other adult vaccinations. For example, hepatitis and shingles vaccines range from $13 to over $200. Reuters reports that since the COVID vaccine is no longer being administered in an "emergency" setting, demand isn't as high. Experts predict demand will soon be comparable to other annual vaccinations such as flu shots. Reuters reports that since COVID boosters have been updated to target Omicron strains, roughly 14.8 million Americans got boosted during the first six weeks of the rollout

Credit: Wibbitz Top Stories    Duration: 01:31Published
India detects the first Omicron BF.7 case, experts advice caution | Oneindia News *News [Video]

India detects the first Omicron BF.7 case, experts advice caution | Oneindia News *News

A new threat from the fast-mutating and more virulent Omicron variant BF.7, also known as Omicron offspring, was reported after the Gujarat Biotechnology Research Centre detected the first case of the sub-variant in India. Two new Omicron sub-variants BF.7 and BA.5.1.7, which are highly infectious with greater transmissibility, were recently detected in several provinces of China. #BF.7Variant #OmicronVariant #IndiaOmicronVariant

Credit: Oneindia    Duration: 03:05Published

COVID-19 COVID-19 Contagious disease caused by SARS-CoV-2

China eases some COVID restrictions following anti-lockdown protests

Chinese authorities have eased some COVID restrictions in selected cities across the country following recent widespread anti-lockdown protests.
Sky News

India's Covid infection tally rises by 226, active caseload declines to 4,529

The number of people who have recuperated from the disease surged to 4,41,38,235, while the case fatality rate was recorded at 1.19 per cent. According to the..
IndiaTimes

Hancock says ministers were told 820,000 people in UK could die from COVID

Matt Hancock has said he was warned the COVID pandemic could kill hundreds of thousands of people in the UK two months before the country was put into lockdown..
Sky News

India reports 253 more Covid cases, 3 deaths

India saw a single-day rise of 253 coronavirus infections, while the active cases have declined to 4,597, the Health Ministry said on Saturday. The toll climbed..
IndiaTimes

Related videos from verified sources

New COVID Boosters To Be Released Before They’re Tested on Humans [Video]

New COVID Boosters To Be Released Before They’re Tested on Humans

New COVID Boosters To Be Released , Before They’re Tested on Humans. According to a 'Wall Street Journal' report, the FDA is set to approve the new booster shots that target Omicron and its..

Credit: Wibbitz Top Stories     Duration: 01:31Published